Reklāma
Forex ziņas
Hawkish Fedspeak Came To The Dollar's Rescue Last Week
A Fed narrative that focused on scaling back rate cut expectations helped the U.S. Dollar trade firm during the week spanning February 5 to February 9.
RTTNews |
549 days ago
Canadian Market Up Firmly In Positive Territory At Noon
The Canadian market is up firmly in positive territory at noon on Monday, with stocks from consumer discretionary, materials, energy and financials sectors posting notable gains.
RTTNews
|
549 days ago
Swiss Franc Slides Against Majors
The Swiss franc fell against its major counterparts in the European session on Monday.
RTTNews
|
549 days ago
Canadian Dollar Climbs Against Most Majors
The Canadian dollar advanced against its most major counterparts in the European session on Monday.
RTTNews
|
549 days ago
Stellantis To Adopt SAE J3400 Charging Connector For Select 2026 BEV Models In North America
Automaker Stellantis N.V. (STLA) announced Monday its adoption of the upcoming SAE J3400 charging connector, starting with select battery-electric vehicle (BEV) models launching in North America for the 2026 model year.
RTTNews
|
549 days ago
NRx Pharmaaeuticals To Receive First $5 Mln Milestone Payment From Partners Alvogen And Lotus Pharma
Biopharmaceutical company NRx Pharmaceuticals, Inc. (NRXP) announced Monday the advance of the first $5 million milestone payment based on the Company's partnership agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.
RTTNews
|
549 days ago
Beamr Imaging Skyrockets 143% As NVIDIA Joins To Accelerate Adoption Of Newest Video Standard - AV1
Beamr Imaging Ltd. (BMR), a provider of video optimization technology and solutions, announced Monday it will present its joint research relating to automated video modernization with NVIDIA Corp. (NVDA) at the ACM Mile-High-Video 2024 conference, being held in Denver, Colorado from February 11-14, 2024.
RTTNews
|
549 days ago
more news
Court Orders Elon Musk To Testify In SEC's Twitter Probe
A U.S. Federal judge ordered Tesla Inc. and SpaceX CEO Elon Musk to testify in an investigation by the U.S. Securities and Exchange Commission regarding his 2022 acquisition of social media platform Twitter, now re-branded as X. The federal regulator is probing whether Musk or anyone else, committed securities fraud in 2022 as he purchased Twitter stock ahead of his buyout of the firm.
RTTNews
|
549 days ago
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis
Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews
|
549 days ago
Bay Street Likely To Open On Subdued Note
Canadian shares are likely to open flat or slightly lower Monday morning, tracking weak crude oil prices. With U.S. inflation data due on Tuesday, the mood is likely to remain cautious and activity is expected to be mostly stock specific.
RTTNews
|
549 days ago
India Inflation Softens On Cooling Food Costs
India consumer price inflation softened to a three-month low in January on moderating food price growth, data from the Ministry of Statistics and Programme Implementation showed Monday. The consumer price index posted an annual growth of 5.10 percent, weaker than the 5.69 percent increase in December, which was the fastest in four months.
RTTNews
|
549 days ago
Visa Adds Digital Wallet Features To Commercial Pay In Collaboration With Conferma Pay
Digital payments firm Visa, Inc. (V) announced Monday extended digital wallet capabilities within Visa Commercial Pay, a suite of B2B payment solutions built in partnership with Conferma Pay, to revolutionize how businesses manage transactions globally.
RTTNews
|
549 days ago
Merck Says Health Canada Oks KEYTRUDA In Combination With Trastuzumab And Chemotherapy
Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, announced Monday that Health Canada has granted approval of KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors express PD-L1 as determined by a validated test.
RTTNews
|
549 days ago
Stay up to date!
Add Ziņas to your browser
Add To Chrome
